Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 36750040)

  • 1. Circulating Glypican-4 Is a Predictor of 24-Month Overall Survival in Metastatic Breast Cancer.
    Muendlein A; Heinzle C; Brandtner EM; Leiherer A; Drexel H; Dechow T; Decker T
    Oncol Res Treat; 2023; 46(4):151-156. PubMed ID: 36750040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating syndecan-1 and glypican-4 predict 12-month survival in metastatic colorectal cancer patients.
    Muendlein A; Severgnini L; Decker T; Heinzle C; Leiherer A; Geiger K; Drexel H; Winder T; Reimann P; Mayer F; Nonnenbroich C; Dechow T
    Front Oncol; 2022; 12():1045995. PubMed ID: 36353562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating glypican-4 is a new predictor of all-cause mortality in patients with heart failure.
    Muendlein A; Heinzle C; Leiherer A; Brandtner EM; Geiger K; Gaenger S; Fraunberger P; Mader A; Saely CH; Drexel H
    Clin Biochem; 2023 Nov; 121-122():110675. PubMed ID: 37844682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum glypican-4 is associated with the 10-year clinical outcome of patients with peripheral artery disease.
    Muendlein A; Heinzle C; Leiherer A; Geiger K; Brandtner EM; Gaenger S; Fraunberger P; Saely CH; Drexel H
    Int J Cardiol; 2022 Dec; 369():54-59. PubMed ID: 35944770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum glypican-4 is a marker of future vascular risk and mortality in coronary angiography patients.
    Muendlein A; Brandtner EM; Leiherer A; Geiger K; Heinzle C; Gaenger S; Fraunberger P; Mader A; Saely CH; Drexel H
    Atherosclerosis; 2022 Mar; 345():33-38. PubMed ID: 35202959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma apolipoprotein M predicts overall survival in metastatic breast cancer patients.
    Muendlein A; Heinzle C; Brandtner EM; Leiherer A; Geiger K; Gaenger S; Drexel H; Dechow T; Decker T
    Breast Cancer Res Treat; 2023 Oct; 201(3):571-576. PubMed ID: 37490173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Cyclin-Dependent Kinases 4 and 6 Inhibitors With Survival in Patients With Hormone Receptor-Positive Metastatic Breast Cancer: A Systematic Review and Meta-analysis.
    Li J; Huo X; Zhao F; Ren D; Ahmad R; Yuan X; Du F; Zhao J
    JAMA Netw Open; 2020 Oct; 3(10):e2020312. PubMed ID: 33048129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib.
    Prat A; Cheang MC; Galván P; Nuciforo P; Paré L; Adamo B; Muñoz M; Viladot M; Press MF; Gagnon R; Ellis C; Johnston S
    JAMA Oncol; 2016 Oct; 2(10):1287-1294. PubMed ID: 27281556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.
    Gao JJ; Cheng J; Bloomquist E; Sanchez J; Wedam SB; Singh H; Amiri-Kordestani L; Ibrahim A; Sridhara R; Goldberg KB; Theoret MR; Kluetz PG; Blumenthal GM; Pazdur R; Beaver JA; Prowell TM
    Lancet Oncol; 2020 Feb; 21(2):250-260. PubMed ID: 31859246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma thymidine kinase 1 activity and outcome of ER+ HER2- metastatic breast cancer patients treated with palbociclib and endocrine therapy.
    Cabel L; Rosenblum D; Lerebours F; Brain E; Loirat D; Bergqvist M; Cottu P; Donnadieu A; Bethune A; Kiavue N; Rodrigues M; Pierga JY; Tanguy ML; Bidard FC
    Breast Cancer Res; 2020 Sep; 22(1):98. PubMed ID: 32928264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dichotomous Effects of Glypican-4 on Cancer Progression and Its Crosstalk with Oncogenes.
    Chérouvrier Hansson V; Cheng F; Georgolopoulos G; Mani K
    Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the Predictive and Prognostic Values of Stromal Tumor-Infiltrating Lymphocytes in HER2-Positive Breast Cancers treated with neoadjuvant chemotherapy.
    Yang X; Rao J; Yang W; Shui R
    Target Oncol; 2018 Dec; 13(6):757-767. PubMed ID: 30406444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GPC4, the gene for human K-glypican, flanks GPC3 on xq26: deletion of the GPC3-GPC4 gene cluster in one family with Simpson-Golabi-Behmel syndrome.
    Veugelers M; Vermeesch J; Watanabe K; Yamaguchi Y; Marynen P; David G
    Genomics; 1998 Oct; 53(1):1-11. PubMed ID: 9787072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the association of serum glypican-4 with prevalent and future kidney function.
    Muendlein A; Brandtner EM; Leiherer A; Geiger K; Heinzle C; Gaenger S; Fraunberger P; Haider D; Saely CH; Drexel H
    Sci Rep; 2022 Jun; 12(1):10168. PubMed ID: 35715556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy.
    Rozenblit M; Mun S; Soulos P; Adelson K; Pusztai L; Mougalian S
    Breast Cancer Res; 2021 Jan; 23(1):14. PubMed ID: 33514405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcomes of tucidinostat-based therapy after prior CDK4/6 inhibitor progression in hormone receptor-positive heavily pretreated metastatic breast cancer.
    Zhou J; Wu X; Zhang H; Wang X; Yuan Y; Zhang S; Jiang Z; Wang T
    Breast; 2022 Dec; 66():255-261. PubMed ID: 36375386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial.
    Park YH; Kim TY; Kim GM; Kang SY; Park IH; Kim JH; Lee KE; Ahn HK; Lee MH; Kim HJ; Kim HJ; Lee JI; Koh SJ; Kim JY; Lee KH; Sohn J; Kim SB; Ahn JS; Im YH; Jung KH; Im SA;
    Lancet Oncol; 2019 Dec; 20(12):1750-1759. PubMed ID: 31668850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer.
    Guan X; Ma F; Li C; Wu S; Hu S; Huang J; Sun X; Wang J; Luo Y; Cai R; Fan Y; Li Q; Chen S; Zhang P; Li Q; Xu B
    Cancer Commun (Lond); 2019 Jan; 39(1):1. PubMed ID: 30606259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic impact of the glypican family of heparan sulfate proteoglycans on the survival of breast cancer patients.
    Grillo PK; Győrffy B; Götte M
    J Cancer Res Clin Oncol; 2021 Jul; 147(7):1937-1955. PubMed ID: 33742285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exosomal miR-1246 and miR-155 as predictive and prognostic biomarkers for trastuzumab-based therapy resistance in HER2-positive breast cancer.
    Zhang Z; Zhang L; Yu G; Sun Z; Wang T; Tian X; Duan X; Zhang C
    Cancer Chemother Pharmacol; 2020 Dec; 86(6):761-772. PubMed ID: 33068176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.